• CStone Pharmaceuticals secured China NMPA clearance for an IND to start clinical trials of CS5007, an EGFR/HER3 bispecific ADC.
• The IND was accepted via the regulator’s fast-track innovative drug review channel, completing review in 23 working days.
• The program supports a global first-in-human Phase I study, which began in Australia in June 2026 with first patient dosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12293407), on August 20, 2026, and is solely responsible for the information contained therein.